文献速递创伤骨科手外科与足踝外科

围手术期酮咯酸如何影响踝关节骨折术后阿片类药物用量与疼痛管理?

How Does Perioperative Ketorolac Affect Opioid Consumption and Pain Management After Ankle Fracture Surgery?
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

这项随机对照研究纳入128例踝关节骨折切开复位内固定患者,比较术后使用或不使用酮咯酸。结果显示酮咯酸组阿片类药物消耗量少于对照组,术后第1、2天疼痛VAS中位数评分更低,但疼痛与睡眠评分获益不明确;12周临床与影像学愈合两组无差异。

要点

  • 酮咯酸组平均消耗14片阿片类药物,少于对照组的19.3片(p=0.037)。
  • 酮咯酸组术后第1、2天疼痛VAS中位数评分低于对照组(p<0.035)。
  • 12周临床愈合(p=0.575)与影像学愈合(p=0.961)两组无差异。

核心结论

  • 在踝关节骨折切开复位内固定术后早期,加用酮咯酸可减少阿片类药物用量,对疼痛的改善效果不一且幅度小;但研究检验效能不足以确定该药在骨折愈合与副作用方面的真实安全性。

研究设计与样本

  • 随机对照试验,2016年8月至2017年12月纳入128例急性踝关节骨折行切开复位内固定患者,术前简单随机分为使用或不使用酮咯酸组。
  • 主要评估术后阿片类药物消耗、VAS疼痛控制及骨折愈合;愈合由治疗外科医生根据术后12周舒适行走能力评估临床愈合,并由两名对患者姓名和手术时间不知情的足踝骨科医生评估影像学愈合。
  • 采用意向性治疗分析;证据等级为Level I(治疗性研究)。

主要发现

  • 酮咯酸组平均消耗14片阿片类药物,少于对照组平均19.3片(p=0.037)。
  • 酮咯酸组术后第1天和第2天疼痛VAS中位数评分低于对照组(p<0.035)。
  • 患者报告的疼痛评分和睡眠评分未明确显示使用酮咯酸获益。
  • 对于12周时踝关节骨折已愈合的患者,两组临床愈合(p=0.575)和影像学愈合(p=0.961)无差异。

关键数值与推荐

  • VAS疼痛改善定义为VAS量表>20 mm/100 mm。
  • 延迟愈合定义为术后12周随访X线片上仍可见骨折线。

临床怎么用

  • 在踝关节骨折切开复位内固定术后早期,加用酮咯酸可帮助患者减少阿片类镇痛药用量。
  • 酮咯酸对疼痛的改善效果不一且幅度小。
  • 该研究检验效能不足以确定酮咯酸在骨折愈合与副作用方面的真实安全性,需更高检验效能的随机研究进一步探讨。

局限性

  • 研究检验效能不足以确定该药在骨折愈合与副作用方面的真实安全性。
  • 参与者未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The investigation of nonnarcotic drug regimens for postoperative pain management is important in addressing the opioid epidemic. NSAIDs can be a powerful adjunct in managing postoperative pain, but the possibility of delayed bone healing is a major concern for orthopaedic surgeons. Our recent retrospective study on ketorolac administration demonstrated that the NSAID is not associated with an increased risk of delayed union or nonunion after ankle fracture surgery. QUESTIONS/PURPOSES: To determine whether postoperative ketorolac (1) reduces opioid consumption, (2) improves VAS pain control, and (3) affects fracture healing after open reduction and internal fixation of ankle fractures. METHODS: Between August 2016 and December 2017, 128 patients undergoing open reduction and internal fixation of an acute ankle fracture were randomized before surgery via simple randomization to treatment with or without ketorolac. No patients changed treatment regimen groups or opted out of randomization. All other aspects of perioperative care were treated identically. A once-daily survey was distributed via email on postoperative Days 1 to 7. Unblinded participants were asked to report their daily opioid consumption, pain level, and sleep interference using the VAS, and pain frequency using a five-point Likert scale, and side effects with the VAS. For VAS pain, > 20 mm/100 mm on the VAS scale was required to be considered "improved." In all, 83% (106 of 128) patients completed all seven postoperative surveys with 14 in the control group and eight in the ketorolac group lost to follow-up. Fifty-six patients were administered ketorolac with opioid medication (treatment group) and 50 were administered opioids alone (control group). Participants were comprised of 42% men (44), and 58% women (62); mean age was 48 years. The treating surgeon assessed clinical healing based on the patient's ability to ambulate comfortably at 12 weeks postoperatively. Radiographic healing was assessed by two fellowship-trained orthopaedic foot and ankle surgeons blinded to the patient's name and time since surgery. The surgeons evaluated randomized standard ankle series (anteroposterior, mortise, and lateral) radiographs for resolution of each fracture line to determine fracture union, with delayed union being defined as fracture lines present on radiographs taken at 12-week postoperative visits. Intention-to-treat analysis was performed. RESULTS: Patients in the treatment group consumed a mean of 14 opioid pills, which was less than the mean of 19.3 opioids pills consumed by patients in the control group (p = 0.037). Patients with ketorolac had lower median VAS scores for pain (p < 0.035) postoperatively on postoperative Days 1 and 2 than did control patients. By contrast, patient-reported pain scores and scores for sleep did not convincingly show a benefit to the use of ketorolac. For patients whose ankle fractures healed at 12 weeks, there was no difference between the groups in terms of clinical healing (p = 0.575) and radiographic healing (p = 0.961). CONCLUSIONS: In this randomized study, adding ketorolac to the postoperative drug regimen decreased the use of opioid medication after open reduction and internal fixation of ankle fractures in the early postoperative period, and there were mixed, small effects on pain reduction. This NSAID is a valuable tool in helping patients manage postoperative pain with less use of narcotic analgesia. However, our study was underpowered to determine the true safety of this drug in terms of fracture healing and side effects and these questions warrant higher-powered randomized study investigation. LEVEL OF EVIDENCE: Level I, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. McDonald EL, Daniel JN, Rogero RG, et al. How Does Perioperative Ketorolac Affect Opioid Consumption and Pain Management After Ankle Fracture Surgery? Clin Orthop Relat Res. 2020. PMID: 31567579. doi:10.1097/CORR.0000000000000978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。